Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
1(11%)
Results Posted
50%(3 trials)

Phase Distribution

Ph phase_2
4
44%
Ph not_applicable
1
11%
Ph phase_1
2
22%
Ph phase_4
2
22%

Phase Distribution

2

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
2(22.2%)
Phase 2Efficacy & side effects
4(44.4%)
Phase 4Post-market surveillance
2(22.2%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(1)
Completed(6)
Terminated(1)
Other(1)

Detailed Status

Completed6
unknown1
Withdrawn1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (22.2%)
Phase 24 (44.4%)
Phase 42 (22.2%)
N/A1 (11.1%)

Trials by Status

completed667%
unknown111%
withdrawn111%
recruiting111%

Recent Activity

1 active trials
Showing 5 of 9
recruitingphase_2

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

NCT06075953
completedphase_2

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

NCT00921115
withdrawnphase_1

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

NCT04316169
completedphase_4

Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)

NCT02959853
completedphase_4

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

NCT01769781
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT06075953Phase 2

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Recruiting
NCT00921115Phase 2

Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.

Completed
NCT04316169Phase 1

Hydroxychloroquine, Abemaciclib and Endocrine Therapy in Hormone Receptor Positive (HR+)/Her 2 Negative Breast Cancer

Withdrawn
NCT02959853Phase 4

Aromatase Inhibitors and Weight Loss in Severely Obese Hypogonadal Male Veterans (Pilot)

Completed
NCT01769781Phase 4

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

Completed
NCT00259090Phase 2

Anti-tumour Effects & Tolerability of Faslodex Alone or in Combination With Arimidex in Post Menopausal Women Prior to Surgery for Primary Breast Cancer

Completed
NCT00309855Phase 1

Testosterone-Driven Growth-Hormone (GH) Secretion in Aging Men

Completed
NCT00983554Not Applicable

Metabolic Effects of Steroids in Obese Men

Unknown
NCT00255463Phase 2

Phase II Neoadjuvant ER+/PgR + Arimidex +/- Iressa Study

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9